Clinical Trial Update: Pilot Study of a Double Isolation Perfusion Schedule Using Melphalan Alone for Intransit Melanoma or Unresectable Sarcoma of the Extremity [Phase 1]

View source ↗

Summary

This is a Phase 1 pilot trial update evaluating melphalan perfusion for in-transit melanoma or unresectable extremity sarcoma, which has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma
• Sarcoma

Drugs mentioned

• Melphalan (Melphalan)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Melanoma, Sarcoma | Phase 1 | Status: COMPLETED